Efficacy and safety of sublingual immunotherapy with grass monomeric allergoid: Comparison between two different treatment regimens

European Annals of Allergy and Clinical Immunology

Volumn 43, Issue 6, 2011, Pages 176-183

  Quercia, O ^a   Bruno, M E ^c   Compalati, E ^b   Falagiani, P ^c   Mistrello, G ^c   Stefanini, G F ^a  

^a Allergological Department   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c Lofarma SpA   (Italy)

Author keywords

Asthma; Grass pollens; Monomeric carbamylated allergoid; Rhinitis; Slit; Sublingual immunotherapy

Indexed keywords

ALLERGEN; CARBAMYLATED MONOMERIC ALLERGOID; CETIRIZINE; FLUTICASONE PROPIONATE; LAIS; METHACHOLINE; PREDNISONE; SALBUTAMOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHMA; BURNING SENSATION; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; GRASS POLLEN; HUMAN; LIP DISEASE; LIP PARESTHESIA; MALE; MORNING DOSAGE; NOCTURNAL ASTHMA; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; SEASON; SORE THROAT; SUBLINGUAL IMMUNOTHERAPY; TABLET; VISUAL ANALOG SCALE; WELLBEING;

ADMINISTRATION, SUBLINGUAL; ADULT; AGED; ANTIGENS, PLANT; ASTHMA; CARBAMATES; CLINICAL PROTOCOLS; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; ITALY; MALE; METHACHOLINE CHLORIDE; MIDDLE AGED; PLANT EXTRACTS; POACEAE; PROSPECTIVE STUDIES; RHINITIS, ALLERGIC, SEASONAL; SEASONS; TREATMENT OUTCOME;

EID: 83755196755     PISSN: 03979148     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bousquet J, Lockey RF, Malling H-J Eds.WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998; 53 (44 suppl): 1-42.
2. Malling HJ, Abreu-Nogueira J, Alvarez-Cuesta E, et al. Local immunotherapy. Allergy 1998; 53: 933-44.
3. Malling HJ, Weeke B. Position Paper immunotherapy of the EAACI. Allergy 1993; 48: 9-35.
4. Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009; 64 Suppl 91: 1-59.
5. Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006; 61: 151-65.
6. Nouri-Aria KT, Wachholz PA, Francis JN, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004; 172: 3252-9.
7. Francis JN, Till SJ, Durham SR. Induction of IL-10+ CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003; 111: 1255-61.
8. Dunski EH, Goldstein MF, Dvorin DJ, Belecanech GA. Anaphylaxis to sublingual immunotherapy. Allergy 2006; 61: 1235.
9. Antico A, Pagani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy 2006; 61: 1236-7.
10. Aiefan AO, Keles S, Bahceciler NN, Barlan IB. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 2007; 62: 567-8.
11. Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy 2008; 63: 374.
12. de Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 2009; 64: 963-4.
13. Mistrello G, Brenna O, Roncarolo D, Zanoni D, Gentili M, Falagiani P. Monomeric chemically modified allergens: immunologic and physicochemical characterization. Allergy 1996; 51: 8-15.
14. Passalacqua G, Albano M, Fregonese L, et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998 Feb 28; 351 (9103): 629-32.
15. Lombardi C, Gargioni S, Melchiorre A, et al. Safety of sublingual immunotherapy with monomeric allergoid in adults: Multicenter post-marketing surveillance study. Allergy 2001; 56: 989-92.
16. Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica GW. Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients. Allergy 1999; 54: 1110-3.
17. Mösges R, Ritter B, Kayoko G, Allekotte S. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais tablets. Acta Dermatovenerol Alp Panonica Adriat 2010; 19 (3): 3-10.
18. Senna G, Ridolo E, Calderon M, Lombardi C, Canonica GW, Passalacqua G. Evidences of adherence to allergen specific immunotherapy. Curr Opin Allergy Clin Immunol 2009; 9 (6): 544-8.
19. Senna G, Lombardi C, Canonica GW, Passalacqua G. How aderent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. J Allergy Clin Immunol 2010; 126 (3): 668-9.
20. Vita D, Caminiti L, Ruggeri P, Pajno GB. Sublingual immunotherapy: adherence based on timing and monitoring control visits. Allergy 2010; 65 (5): 668-9.
21. Allergic Rhinits and its Impact on Asthma. Bousquet J and Van Cauwenberge P edts. J Allergy Clin Immunol 2001; 108 (5 supp): S146-150.
22. Global Initiative for Asthma, National Institute of Health, National Heart Lung and Blood Institute. Global strategy for asthma management and prevention. NHLBI/WHO workshop report no. 02-9. Bethesda, NHLBI, 200.
23. Lombardi C, Braga M, Incorvaia C, Senna G, Canonica GW, Passalacqua G. Administration regimens for sublingual immunotherapy. What do we know? Allergy 2009; 64 (6): 849-54.
24. Calderon MA, Birk AO, Andersen JS, Durham SR. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy. Allergy 2007; 62 (8): 958-61.
25. Bousquet PJ, Combescure C, Klossek JM, Daurès JP, Bousquet J. Changes in visual analogue scale in a pragmatic randomized cluster trial of allergic rhinitis. J Allergy Clin Immunol 2009; 123: 1349-54.
26. Carlsen KH. Clinical relevance of bronchial hyperresponsiveness. Pediatr Allergy Immunol 1996; 7 (9 Suppl): 34-8.
27. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010; (8): CD001186
28. Crimi E, Voltolini S, Gianiorio P, et al. Effect of seasonal exposure to pollen on specific bronchial sensitivity in allergic patients. J Allergy Clin Immunol 1990; 85 (6): 1014-9.
29. Cosmi L, Santarlasci V, Angeli R, et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon- gamma- and interleukin-10-production. Clin Exp Allergy 2006; 36 (3): 261-72.
30. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117 (4): 802-9.
31. Hrobjartsson A, Gotzsche PC. Is the placebo powerless. An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001; 344: 1594-602.
32. Calderon M, Essendrop M. Specific immunotherapy with high dose SQ standardized grass allergen tablets was safe and well tolerated. J Invest Clin Immunol 2006; 16: 338-44.